Adaptive Designs in Clinical Trials 2019
SMi Group are proud to announce the 11th annual Adaptive Designs in Clinical Trials conference and exhibition will return to London from the 1st – 2nd April 2019. With the growing popularity in use and acceptance of adaptive designs in clinical trials - demonstrated most recently with the new FDA draft guidance on adaptive designs – there is a pressing need for a forum which explores this increasingly normalized medical methodology.
Hosting in depth presentations from regulatory agencies, researchers and biostatisticians, the meeting will cover how personalized medicine, platform trials, response-adaptive randomization, signature designs, estimand framework, Bayesian methods and digital innovation are revolutionizing the drug development process both in Europe and North America.
The benefits of attending:
At this year’s conference there will once again be an array of networking opportunities:
- Meet and network with key industry and thought leaders shaping state of the art adaptive design techniques
- More than 4 hours of networking during the conference days
- Engage with an array of vendors, with leading solution providers, Mevia and GCE Solutions among those exhibiting last year
Key reasons to attend:
- See how the regulatory environment for adaptive drug design is shifting across the continent with insights from the MHRA, Amgen, AstraZeneca and Berry Consulting
- Explore the therapeutic potential of adaptive designs with real-world examples from H.Lundbeck, GSK Vaccines, Pfizer and Novartis
- Listen to how the latest platform trial case studies – such as that of the EPAD project and the MS Society initiative, are impacting pharmaceutical development
- Delve into the long-standing discussion of Bayesian vs. frequentist designs
- Discover the latest research in response-adaptive designs: trials for rare diseases and looking forward
Chairs for 2019:
Alex Sverdlov, Director, Statistical Scientist, Novartis
Tom Parke, Director of Software Solutions, Berry Consulting
Featured Speakers:
- Sandeep Menon, Vice President and Head of Early Clinical Development, Pfizer
- Simon Wandel, Associate Director, Statistical Methodology and Consulting, Novartis
- Solange Corriol-Rohou, Senior Director Regulatory Addairs & Policy, Europe, AstraZeneca*
- Christine Fletcher, Executive Director Biostatistics, Amgen
- Philip Hougaard, Vice President Biometrics, H. Lundbeck
- Beatrice Panico, Medical Assessor, MHRA
- Kaspar Rufi bach, Principal Statistical Scientist, Roche
- Andrea Callegaro, Senior Manager, Biostatistician, GSK Vaccines
EARLY-BIRD RATES:
- BOOK BY 14 DECEMBER AND SAVE £400
- BOOK BY 31 JANUARY AND SAVE £200
- BOOK BY 14 FEBRUARY AND SAVE £100
Additional Contact Info:
T: +44 (0)20 7827 6088
LinkedIn: @SMi Pharma
Twitter: #SMi & #smiadaptivedesigns